Selective inhibition of c-Myc/max dimerization by a pyrazolo[1,5-a]- pyrimidine

ChemMedChem

Volumn 2, Issue 5, 2007, Pages 627-630

  Kiessling, Anke ^a   Wiesinger, Rita ^a   Sperl, Bianca ^a   Berg, Thorsten ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

Inhibitors; Protein protein interactions; Screening; Signal transduction; Transcription factor dimerization

Indexed keywords

BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; MYC ASSOCIATED FACTOR X; MYC PROTEIN; PYRAZOLE DERIVATIVE; PYRAZOLO(1,5 A)PYRIMIDINE; PYRAZOLO(1,5-A)PYRIMIDINE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CHEMISTRY; DIMERIZATION; DRUG ANTAGONISM; HUMAN;

BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL LINE; DIMERIZATION; HUMANS; PROTO-ONCOGENE PROTEINS C-MYC; PYRAZOLES; PYRIMIDINES;

EID: 42149091567     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200600294     Document Type: Article

References (22)

1. S. Adhikary, M. Eilers, Nat. Rev. Mol. Cell Biol. 2005, 6, 635-645.
2. S. Pelengaris, M. Khan, G. Evan, Nat. Rev. Cancer 2002, 2, 764-776.
3. C. Grandori, S. M. Cowley, L. P. James, R. N. Eisenman, Annu. Rev. Cell Dev. Biol. 2000, 16, 653-699.
4. C. V. Dang, Mol. Cell. Biol. 1999, 19, 1-11.
5. T. Berg, S. B. Cohen, J. Desharnais, C. Sonderegger, D. J. Maslyar, J. Goldberg, D. L. Boger, P. K. Vogt, Proc. Natl. Acad. Sci. USA 2002, 99, 3830-3835.
6. X. Yin, C. Giap, J. S. Lazo, E. V. Prochownik, Oncogene 2003, 22, 6151-6159.
7. Y. Xu, J. Shi, N. Yamamoto, J. A. Moss, P. K. Vogt, K. D. Janda, Bioorg. Med. Chem. 2006, 14, 2660-2673.
8. I. D'Agnano, A. Valentini, G. Gatti, A. Chersi, A. Felsani, J. Cell. Physiol. 2007, 210, 72-80.
9. S. K. Nair, S. K. Burley, Cell 2003, 112, 193-205.
10. A. Kiessling, B. Sperl, A. Hollis, D. Eick, T. Berg, Chem. Biol. 2006, 13, 745-751.
11. A. R. Ferre-D'Amare, G. C. Prendergast, E. B. Ziff, S. K. Burley, Nature 1993, 363, 38-45.
12. J. Schust, T. Berg, Anal. Biochem. 2004, 330, 114-118.
13. B. Amati, K. Alevizopoulos, J. Vlach, Front. Biosci. 1998, 3, d250-268.
14. R. Hopewell, E. B. Ziff, Mol. Cell. Biol. 1995, 15, 3470-3478.
15. For a patent protecting the use of pyrazolo[1, 5-a]pyrimidines as Na-channel inhibitors, see R. N. Atkinson, M. F. Gross, M. A. Van Rhee, PCT WO 03/037900 A2,, 2003.
16. For a patent protecting the use of pyrazolo[1, 5-a]pyrimidines as 11β-hydroxysteroid dehydrogenase type 1 inhibitors, see H. S. Andersen, G. C. T. Kampen, I. T. Christensen, J. P. Mogensen, A. R. Larsen, PCT WO 2004/089471 A2, 2004.
17. J. H. Patel, A. P. Loboda, M. K. Showe, L. C. Showe, S. B. McMahon, Nat. Rev. Cancer 2004, 4, 562-568.
18. P. K. Vogt, Nat. Rev. Cancer 2002, 2, 465-469.
19. H. D. Arndt, Angew. Chem. 2006, 118, 4664-4673;
20. Angew. Chem. Int. Ed. 2006, 45, 4552-4560.
21. H. Mo, M. Henriksson, Proc. Natl. Acad. Sci. USA 2006, 103, 6344-6349.
22. H. Mo, M. Vita, M. Crespin, M. Henriksson, Cell Cycle 2006, 5, 2191-2194.